Atara Biotherapeutics is a drug development company focused on innovative therapies for serious debilitating diseases. The company is publicly traded on Nasdaq under ATRA and was founded in 2012.
Class action lawsuits allege securities violations by Atara Biotherapeutics and Inovio Pharmaceuticals related to FDA submissions. Atara faces claims over manufacturing issues with its tabelecleucel BLA, while Inovio is accused of misleading statements about INO-3107 regulatory timelines and manufacturing deficiencies.
Atara Biotherapeutics announced a Type A meeting with the FDA to discuss the Complete Response Letter for tabelecleucel's Biologics License Application, held by partner Pierre Fabre Pharmaceuticals.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06429800 |
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus |
WITHDRAWN | PHASE1 |
| NCT06256484 |
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
TERMINATED | PHASE1 |
| NCT04577326 |
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03769467 |
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
TERMINATED | PHASE1/PHASE2 |
| NCT03283826 |
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis |
TERMINATED | PHASE1/PHASE2 |
| NCT03010332 |
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease |
NO_LONGER_AVAILABLE | |
| NCT02822495 |
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies |
NO_LONGER_AVAILABLE | |
| NCT01646645 |
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation |
COMPLETED | PHASE2 |
| NCT01498484 |
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies |
COMPLETED | PHASE2 |
| NCT00620633 |
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation |
COMPLETED | PHASE1 |
